Key Highlights
- Dr. Alan Saghatelian named Chief Technology Officer at Velia Therapeutics.
- Scientific co-founder with over 25 years of research experience in microproteins.
- Dr. Saghatelian to oversee the development of Velia’s microprotein-based platform.
Source: Business Wire
Notable Quotes
- “I am thrilled that Dr. Saghatelian, a renowned expert in human biology and co-founder of Velia, will assume the role of chief technology officer.” — John McHutchison, AO, MD, President and CEO at Velia Therapeutics
- “Welcoming him as chief technology officer is a full-circle moment, especially at a critical time for Velia as we continue to uncover the therapeutic potential of microproteins to fulfill significant unmet needs across therapeutic areas. I look forward to continuing to collaborate with him in his new role at Velia.” — Leon Chen, Chairman of the Board at Velia Therapeutics
SoHC's Take
The appointment of Dr. Alan Saghatelian as Chief Technology Officer marks a significant milestone for Velia Therapeutics. As a pioneer in the study of microproteins, Dr. Saghatelian’s deep expertise will be crucial in advancing Velia’s cutting-edge platform and therapeutic pipeline. His dual role at The Salk Institute and Velia not only strengthens the company’s leadership but also enhances its capacity to innovate and address unmet medical needs through groundbreaking microprotein-based therapies. This strategic move positions Velia Therapeutics to potentially transform the landscape of protein-based therapeutics, offering new hope in treating complex diseases.
